Beranda › Limfoma Non-Hodgkin › Texas › Dallas
Uji klinis Limfoma Non-Hodgkin di Dallas, TX
17 studi untuk Limfoma Non-Hodgkin mencari peserta di lokasi sekitar Dallas (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Menerima pesertaFase 2
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Menerima pesertaFase 1/2
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
- University of Texas Southwestern, Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
- Texas Oncology - DFW (Sammons CC), Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 1
- Baylor University Medical Center, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Menerima pesertaFase 1/2
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Menerima pesertaStudi observasional
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
Menerima pesertaFase 2
- UT Southwestern Medical Center, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Menerima pesertaFase 1/2
- University of Texas Southwestern Medical Center, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- University of Texas Southwestern, Dallas
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Menerima pesertaFase 1
- UT Southwestern Medical Center, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Menerima pesertaStudi observasional
- Ut Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Dallas
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Menerima pesertaStudi observasional
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Menerima pesertaFase 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Menerima pesertaFase 1/2
- UT Southwestern Medical Center, Dallas
Uji klinis Limfoma Non-Hodgkin di kota lain
- New York City, NY31 studi
- Houston, TX31 studi
- Boston, MA26 studi
- Nashville, TN21 studi
- Philadelphia, PA20 studi
- Baldwin Park, CA19 studi
- Washington, DC18 studi
- Chicago, IL18 studi
- Atlanta, GA18 studi
- Milwaukee, WI18 studi
- Columbus, OH18 studi
- Seattle, WA16 studi
Studi lain di Dallas
- Kanker Payudara55 studi
- Kanker Paru Non-Sel Kecil52 studi
- Kanker Metastatik42 studi
- Gagal Jantung42 studi
- Kanker (semua jenis)37 studi
- Kanker Prostat36 studi
- Kanker Kolorektal33 studi
- Obesitas30 studi
- Kanker Ovarium28 studi
- Kanker Paru27 studi
- Kanker Kandung Kemih27 studi
- Kanker Endometrium24 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.